Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 23

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
ivable, net12,637 10,919 Inventories4,960 4,181 Prepaid expenses and other5,197 4,927 Total current assets29,261 25,582 Investments310 279 Property and equipment, net5,283 5,134 Intangible assets, net57,031 60,068 Goodwill35,638 34,956 Other assets9,659 9,142 Total assets$137,182 $135,161 Liabilities and Equity Current liabilitiesShort-term borrowings$5,556 $— Current portion of long-term debt and finance lease obligations1,966 6,804 Accounts payable and accrued liabilities32,245 31,945 Total current liabilities39,767 38,749 Long-term debt and finance lease obligations62,959 60,340 Deferred income taxes2,554 2,579 Other long-term liabilities32,040 30,129 Commitments and contingenciesStockholders' equity (deficit)Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,837,290,114 shares issued as of June 30, 2025 and 1,831,594,494 as of December 31, 202418 18 Common stock held in treasury, at cost, 70,829,000 shares as of June 30, 2025 and 66,337,508 as of December 31, 2024(9,147)(8,201)Additional paid-in capital21,987 21,333 Accumulated deficit(11,503)(7,900)Accumulated other comprehensive loss(1,538)(1,925)Total stockholders' equity (deficit)(183)3,325 Noncontrolling interest45 39 Total equity (deficit)(138)3,364 Total liabilities and equity $137,182 $135,161 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 3

AbbVie Inc. and Subsidiaries Condensed Consolidated Statements of Equity (Deficit) (unaudited)

(in millions)Common shares outstandingCommon stockTreasury stockAdditional paid-in capitalAccumulated deficitAccumulated other comprehensive lossNoncontrolling interestTotalBalance at March 31, 20241,